OMEROS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementOmeros Corp • January 6th, 2016 • Pharmaceutical preparations • New York
Omeros Corporation, a Washington corporation (the “Company”), confirms its agreement (this “Agreement”), with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Omeros Corporation Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • March 1st, 2021 • Omeros Corp • Pharmaceutical preparations • New York
Omeros Corporation, a Washington corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
OMEROS CORPORATION 3,816,793 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 6th, 2019 • Omeros Corp • Pharmaceutical preparations • New York
LEASELease • February 1st, 2012 • Omeros Corp • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 27th day of January, 2012 (the “Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”).
OMEROS CORPORATION and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of November 15, 2018 6.25% Convertible Senior Notes due 2023Indenture • November 15th, 2018 • Omeros Corp • Pharmaceutical preparations • New York
INDENTURE, dated as of November 15, 2018, between Omeros Corporation, a Washington corporation, as issuer (the “Company”), and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States, as trustee (the “Trustee”).
OMEROS CORPORATION and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 14, 2020 SENIOR DEBT SECURITIESIndenture • August 14th, 2020 • Omeros Corp • Pharmaceutical preparations
INDENTURE, dated as of August 14, 2020, between Omeros Corporation, a corporation duly organized and existing under the laws of the State of Washington (herein called the “Company”), having its principal executive office at 201 Elliott Avenue West, Seattle, Washington 98119, and Wells Fargo Bank, National Association, a national banking association organized and existing under the laws of the United States, as Trustee (herein called the “Trustee”).
Shares OMEROS CORPORATION Common Stock ($0.01 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • January 9th, 2008 • Omeros Corp • New York
Omeros Corporation, a Washington corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as Representative (the “Representative”) an aggregate of ___shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to ___additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
COMMON STOCK PURCHASE AGREEMENT Dated as of May 10, 2011 by and between OMEROS CORPORATION and AZIMUTH OPPORTUNITY LTD.Common Stock Purchase Agreement • May 10th, 2011 • Omeros Corp • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 10th day of May, 2011 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Omeros Corporation, a corporation organized and existing under the laws of the State of Washington (the “Company”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in Annex A hereto.
ContractOmeros Corp • May 19th, 2016 • Pharmaceutical preparations • Washington
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 29th, 2010 • Omeros Corp • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 28, 2010, is by and between Omeros Corporation, a Washington corporation (the “Company”), and Azimuth Opportunity, Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 8th, 2019 • Omeros Corp • Pharmaceutical preparations • Washington
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 2, 2019 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and OMEROS CORPORATION, a Washington corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
OMEROS CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • August 14th, 2020 • Omeros Corp • Pharmaceutical preparations • New York
OMEROS CORPORATION PURCHASE AGREEMENTPurchase Agreement • November 15th, 2018 • Omeros Corp • Pharmaceutical preparations • New York
OMEROS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementOmeros Corp • December 14th, 2012 • Pharmaceutical preparations • New York
Omeros Corporation, a Washington corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
TERM LOAN AGREEMENTLoan Agreement • November 9th, 2016 • Omeros Corp • Pharmaceutical preparations • New York
TERM LOAN AGREEMENT, dated as of October 26, 2016 (this “Agreement”), among OMEROS CORPORATION, a Washington corporation (“Borrower”), the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG Servicing”), as administrative agent and collateral agent for the Lenders (in such capacities, together with its successors and assigns, “Administrative Agent”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 25th, 2010 • Omeros Corp • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of October 21, 2010 (the “Closing Date”) between OXFORD FINANCE CORPORATION (“Lender”), and OMEROS CORPORATION, a Washington corporation (“Borrower”), provides the terms on which Lender shall lend to Borrower and Borrower shall repay Lender. The parties agree as follows:
LOAN AND SECURITY AGREEMENT No. V08302Loan and Security Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Illinois
This Loan and Security Agreement (this “Loan Agreement”), made as of September 12, 2008 by and between BlueCrest Capital Finance, L.P. (“Lender”), a Delaware limited partnership with its principal place of business at 225 West Washington Street, Suite 200, Chicago, Illinois 60606, and Omeros Corporation (“Borrower”), a Washington corporation with its principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, WA 98101.
WARRANT TO PURCHASE SHARES OF COMMON STOCK OF OMEROS CORPORATION Dated as of April 12, 2018 Void after the date specified in Section 8Omeros Corp • April 13th, 2018 • Pharmaceutical preparations • Washington
THIS CERTIFIES THAT, for value received, CRG PARTNERS III – PARALLEL FUND “A” L.P., or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Omeros Corporation, a Washington corporation (the “Company”), shares of the Company’s common stock, par value $0.01 per share (such shares, the “Shares” and such common stock, the “Common Stock”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in Amendment No. 3 to Loan Agreement, dated as of April 10, 2018, by and among the Company, CRG Servicing LLC, as administrative and collateral agent, and the lenders party thereto, which amends that certain Term Loan Agreement, dated as of October 26, 2016 (as so amended a
OMEROS CORPORATION SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 12th, 2010 • Omeros Corp • Pharmaceutical preparations • Washington
This Amended and Restated Employment Agreement (the “Agreement”) is dated as of April 7, 2010 (the “Effective Date”) by and between Dr. Gregory A. Demopulos (“Employee”) and Omeros Corporation, a Washington corporation (the “Company”).
EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and MEDICAL RESEARCH COUNCILExclusive License and Sponsored Research Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 31st day of October 2005 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Medical Research Council, a United Kingdom governmental institution having a place of business at 20 Park Crescent, London, United Kingdom, W1B 1AL (“MRC”).
EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and the UNIVERSITY OF LEICESTERExclusive License and Sponsored Research Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 10th day of June 2004 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”).
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This Commercial Supply Agreement (this “Agreement”) is made as of the 9th day of October, 2007 (the “Effective Date”) by and between Omeros Corporation, a Washington corporation, having its principal offices at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101 (“Omeros”), and Hospira Worldwide Inc., a Delaware corporation, having its principal offices at 275 North Field Drive, Lake Forest, Illinois 60045 (“Hospira”). Omeros and Hospira previously entered into a Master Development Agreement, dated May 8, 2007 (the “Development Agreement”), pertaining to the development of Omeros’ pharmaceutical drug product OMS103HP-S. Omeros and Hospira now desire to enter into an agreement for the commercial supply of OMS103HP-S by Hospira to Omeros. Therefore, in consideration of the mutual covenants and obligations set forth below, Omeros and Hospira (the “Parties” and each a “Party”) agree as follows:
SECURITY AGREEMENTSecurity Agreement • October 27th, 2016 • Omeros Corp • Pharmaceutical preparations • New York
SECURITY AGREEMENT dated as of October [●], 2016, among OMEROS CORPORATION, a Washington corporation (“Borrower”), the Subsidiary Guarantors from time to time party hereto (collectively with Borrower and each entity that becomes a “Grantor” hereunder as contemplated by Section 5.12, the “Grantors” and each, a “Grantor”) and CRG SERVICING LLC, a Delaware limited liability company, as administrative agent and collateral agent for the Lenders (in such capacities, together with its successors and assigns, the “Administrative Agent”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).
LEASE AGREEMENTLease Agreement • January 9th, 2008 • Omeros Corp
THIS LEASE AGREEMENT is made as of this 28th day of September 2001, between Alexandria Real Estate Equities, Inc., a Maryland corporation (“Landlord”), and PRIMAL, INC., a Washington corporation (“Tenant”).
DATED 20 April 2007 Scottish Biomedical Limited Telford Pavilion, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, Scotland, U.K. “Scottish Biomedical” or “SB” and Omeros Corporation 1420 Fifth Avenue, Suite 2600 Seattle, WA 98101, U.S.A....Services and Materials Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION
AMENDMENT NO. 1 TO LOAN AGREEMENTLoan Agreement • October 17th, 2017 • Omeros Corp • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO LOAN AGREEMENT, dated as of October 11, 2017 (this “Amendment”), is made among Omeros Corporation, a Washington corporation (“Borrower”), CRG Servicing LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”), and the lenders listed on the signature pages hereof (each, a “Lender” and, collectively, the “Lenders”), with respect to the Loan Agreement referred to below.
COMMON STOCK PURCHASE AGREEMENT Dated as of July 28, 2010 by and between OMEROS CORPORATION and AZIMUTH OPPORTUNITY, LTD.Common Stock Purchase Agreement • July 29th, 2010 • Omeros Corp • Pharmaceutical preparations • New York
Reference is made to the Common Stock Purchase Agreement dated as of July 28, 2010, (the “Purchase Agreement”) between Omeros Corporation, a corporation organized and existing under the laws of the State of Washington (the “Company”), and Azimuth Opportunity, Ltd., an international business company incorporated under the laws of the British Virgin Islands. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement. In accordance with and pursuant to Section 3.1 of the Purchase Agreement, the Company hereby issues this Fixed Request Notice to exercise a Fixed Request for the Fixed Amount Requested indicated below.
AMENDMENT dated 30 April 2007 of the SERVICES AND MATERIALS AGREEMENT dated 20 April 2007 By and between SCOTTISH BIOMEDICAL LIMITED T/A “SCOTTISH BIOMEDICAL” and OMEROS CORPORATIONServices and Materials Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations
This is an amendment (this “Amendment”) effective 30 April 2007, between Scottish Biomedical Limited T/A “Scottish Biomedical” (“Scottish Biomedical”) and Omeros Corporation (“Omeros”) of the Services and Materials Agreement dated 20 April 2007 (“the Agreement”) related to Omeros’ PDE10 program.
OMEROS CORPORATION 6,900,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 14th, 2020 • Omeros Corp • Pharmaceutical preparations • New York
Third Amendment to Pharmaceutical Manufacturing and Supply AgreementAnd Supply Agreement • March 16th, 2017 • Omeros Corp • Pharmaceutical preparations
This is an Amendment (this “Amendment”) to the Pharmaceutical Manufacturing and Supply Agreement dated March 5, 2014, as previously amended July 7, 2015 and August 24, 2016 between DSM Pharmaceuticals, Inc. (“DSM”) and Omeros Corporation (“Omeros”) (the “Master Agreement”), and is entered into as of December 05, 2016 (the “Amendment Effective Date”). All initially capitalized terms in this Amendment shall have the same meaning as set forth in the Master Agreement unless otherwise defined herein.
SETTLEMENT AGREEMENTSettlement Agreement • May 24th, 2018 • Omeros Corp • Pharmaceutical preparations • Delaware
Plaintiffs Omeros Corporation (hereinafter “Omeros”), and Defendants Lupin Ltd and Lupin Pharmaceuticals, Inc. (hereinafter collectively “Lupin”), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of this action and have set forth those terms and conditions in a Settlement Agreement (the “Settlement Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this action as follows:
OMEROS CORPORATION AGREEMENT FOR ANTIBODY DEVELOPMENTAgreement for Antibody Development • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Agreement for Antibody Development (this “Agreement”) is between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and North Coast Biologics LLC (“North Coast”), a Washington Limited Liability Company having an address at 2815 Eastlake Avenue East, #300, Seattle, Washington 98102, and is effective as of October 31, 2008 (the “Effective Date”). Omeros and North Coast may be referred to herein each as a “Party” or together as the “Parties”.
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 9th, 2008 • Omeros Corp • Washington
This Indemnification Agreement (this “Agreement”) is made as of _________, ___ by and between Omeros Corporation, a Washington corporation (the “Company”), and _________ (“Indemnitee”), for good and valuable consideration as set forth below.
AGREEMENT FOR ANTIBODY DISCOVERY AND DEVELOPMENTAgreement for Antibody Discovery and Development • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • California
This is an Agreement between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and Affitech AS (“Affitech”), having an address at Oslo Research Park, Gaustadalléen 21, N-0349 Oslo, Norway, and is effective as of July 25, 2008 (the “Effective Date”). Omeros and Affitech may be referred to herein each as a “Party” or together as the “Parties”.
